Date & Time of Session - 10/23/25 - from 12-1PM

Overview
The Brown Cancer Center at UofL Health continues to expand its services provided to patients with a variety of oncologic diseases. As a result, the health system sees patients with risk factors for OI on a regular basis; however, recent education has not been shared with members of the healthcare team that are involved in the care of this vulnerable patient population. In efforts to reduce the risk of potential complications in this population, it is necessary to educate care team members on identifying patients at risk for OI, sharing OI prophylaxis recommendations, and reviewing new guideline updates related to OI prophylaxis strategies in the oncology population.

Objectives
Upon completion of this activity, the participant will be able to:
1. Review pathogens of interest and patient specific risk factors for opportunistic infection (OI) in the oncology population.
2. Discuss patient specific OI prophylaxis strategies in the oncology population.
3. Evaluate the recent revisions to the cytomegalovirus guidelines for hematopoietic cell transplant and cellular therapy recipients and highlight how they differ from earlier recommendations

Speakers
Ashley Adkins, PharmD
PGY2 Oncology Pharmacy Resident
UofL Health – Louisville, Kentucky

    Session date: 
    10/23/2025 - 12:00pm EDT to 12/21/2025 - 11:59pm EST
    • 1.00 ACPE

      In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

      This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

    Please login or register to take this course.
    Faculty List: 
    Speaker(s)

    Ashley Adkins, PharmD

    has no relevant financial relationships to disclose at this time.